Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189932 | 0.79 | PDPK1 (0.48) | ALDH1A1PDPK1DAOKDM4ETSHR | |
| SCHEMBL988816 | 0.70 | PDPK1 (0.50) | ALDH1A1PDPK1DAOKDM4ETSHR | |
| SCHEMBL13558618 | 0.69 | PARP1 (0.53) | ALDH1A1MEN1KMT2AMAPK1PDPK1 | |
| Piperidine SCHEMBL9045041 | 0.68 | PDPK1 (0.39) | PDPK1DAOKDM4ETSHRHTT | |
| SCHEMBL3233768 | 0.68 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPK1DAO | |
| SCHEMBL20630920 | 0.68 | PDPK1 (0.50) | ALDH1A1MEN1KMT2AMAPK1PDPK1 | |
| SCHEMBL6299913 | 0.67 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL17109319 | 0.67 | PARP1 (0.55) | ALDH1A1MEN1KMT2APDPK1DAO | |
| SCHEMBL1285397 | 0.64 | PDPK1 (0.46) | ALDH1A1PDPK1DAOMAPTTSHR | |
| SCHEMBL20631258 | 0.64 | PARP1 (0.64) | ALDH1A1MEN1KMT2AMAPK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224257-B1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM IND CO LTD (KR) | 2019-10-16 | — | — | EP | disclosed |
| EP-3224257-B1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM IND CO LTD (KR) | 2019-10-16 | — | — | EP | disclosed |
| US-10160770-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-12-25 | — | — | US | disclosed |
| US-20180312521-A1 | METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2018-11-01 | — | — | US | disclosed |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-08-07 | — | — | US | disclosed |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-08-07 | — | — | US | disclosed |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | HANMI PHARM. CO., LTD. (KR) | 2018-08-07 | — | — | US | disclosed |
| US-20170369504-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2017-12-28 | — | — | US | disclosed |
| US-20170369504-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2017-12-28 | — | — | US | disclosed |
| EP-3224257-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2017-10-04 | — | — | EP | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1686119-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1263740-B1 | PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20040097525-A1 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM PLC | 2004-05-20 | — | — | US | disclosed |
| US-6649619-B1 | 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl) benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimeth ylenepyrimidin-4-one or salt; lipoprotein-associated phospholipase A inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-11-18 | — | — | US | disclosed |
| US-20020103213-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312521-A1 | METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | TK1, ERBB2, ABL1 | ALDH1A1 1019/4885MEN1 2011/4885KMT2A 2584/4885 |
| US-10160770-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | TK1, ERBB2, ABL1 | ALDH1A1 1019/4885MEN1 2011/4885KMT2A 2584/4885 |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | ALDH1A1 1423/4885MEN1 2990/4885KMT2A 3374/4885 |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | PLA2G7, PLAT, PLA2G1B | ALDH1A1 664/4885MEN1 3518/4885KMT2A 2745/4885 |
| US-20170369504-A1 | NOVEL METHOD FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN | ERBB2, ERBB4, ABL1 | ALDH1A1 1412/4885MEN1 2735/4885KMT2A 2459/4885 |
| US-10040801-B2 | Method for preparing thienopyrimidine compound and intermediates used therein | ERBB2, ABL1, TK1 | ALDH1A1 1146/4885MEN1 2259/4885KMT2A 2495/4885 |
| US-20040097525-A1 | For therapy of atheroscelerosis | LYPLA2, LOXL2, LYPLA1 | ALDH1A1 623/4885MEN1 2497/4885KMT2A 2375/4885 |
| US-20020103213-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, ENPP2, LYPLA2 | ALDH1A1 732/4885MEN1 2496/4885KMT2A 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.